The medicine "Symbicort Turbuhaler" (or simply "Symbicort") is determined by the instructions for use as an inhalation drug intended for the treatment of obstructive diseases of the respiratory system.
Among the main advantages of this drug, there is a rapid decrease in the manifestation of bronchospasm (within the first two to three minutes), the possibility of a single use per day, and at the same time, prolonged control of bronchial asthma. In addition, the tool "Symbicort", the instructions to which this confirms, increases adherence to therapy with inhaled corticosteroids.
As for the pharmacokinetics of this medication, its bronchodilator effect occurs very quickly and persists for twelve hours after taking a single dose.
The medicine "Symbicort" is produced, the instructions for use of which are mandatory in the kit, in the form of a powder for inhalation. Each dose contains 320 μg of micronized micronized fine budesonide and 9 μg formoterol fumarate dihydrate as active ingredients. An auxiliary ingredient is a substance such as lactose monohydrate.
The Symbicort inhalation agent is recommended to be prescribed by the application as an effective supportive therapy for patients with bronchial asthma. In the chronic form of obstructive pulmonary disease, occurring with periodic exacerbations, the purpose of this drug is also shown.
To use the medicine "Symbicort" the instructions for use categorically forbids people suffering from individual intolerance to budesonide, inhaled lactose or formoterol. Patients under the age of six should also refrain from taking this inhaled drug. In addition, the list of direct contraindications includes lactose intolerance, lactase deficiency and glucose-galactose type malabsorption.
With extreme caution, this medicine is prescribed for pulmonary tuberculosis, thyrotoxicosis, diabetes mellitus and severe arterial hypertension. Patients with viral, fungal or bacterial diseases of the respiratory system should also not take the drug "Symbicort". Doctors' reviews also indicate the undesirability of its administration to people with uncontrolled hypokalemia, severe heart failure, pheochromocytoma, ischemic disease, idiopathic subaortic stenosis, tachyarrhythmia or aneurysm of any localization.
If we talk about the possible side effects provoked by taking the Symbicort medication, then first of all, tachycardia, headache, nausea, palpitations, muscle cramps, tremors, coughing, sleep disturbance and dizziness should be highlighted. In addition, itching, urticaria, angioedema, exanthema, hypokalemia, hyperglycemia, angina pectoris and glaucoma may occur. Some patients also report increased arousal, anxiety, taste disturbance, and a tendency to depression.